Rituximab-Induced Serum Sickness-Like Reaction: A Histopathologic Viewpoint.

Am J Dermatopathol

*Section of Dermatopathology, Department of Dermatology, Boston University School of Medicine, Boston, MA †Department of Dermatology, Boston University School of Medicine, Boston, MA.

Published: April 2016

Download full-text PDF

Source
http://dx.doi.org/10.1097/DAD.0000000000000356DOI Listing

Publication Analysis

Top Keywords

rituximab-induced serum
4
serum sickness-like
4
sickness-like reaction
4
reaction histopathologic
4
histopathologic viewpoint
4
rituximab-induced
1
sickness-like
1
reaction
1
histopathologic
1
viewpoint
1

Similar Publications

The patient was a 38-year-old man who was admitted to our hospital with fever, vomiting and unclear speech. Blood tests showed hemolytic anemia, thrombocytopenia, and elevated creatinine, and a Coombs test was negative. ADAMTS13 activity was <1% and ADAMTS13 inhibitor was 0.

View Article and Find Full Text PDF
Article Synopsis
  • Focal segmental glomerulosclerosis (FSGS) is a significant cause of kidney failure in children, predominantly presenting as idiopathic cases which often recur after transplantation.
  • Early treatment involving plasmapheresis and rituximab was evaluated in a study of pediatric kidney transplant recipients, showing that 75% experienced recurrence of FSGS post-transplant.
  • The results demonstrated that plasmapheresis led to remission in all patients, and rituximab helped further sustain remission and reduce the need for plasmapheresis, with minimal adverse effects noted.
View Article and Find Full Text PDF

Key Clinical Message: Rituximab-induced serum sickness (RISS) is a rare complication of Rituximab (RTX) in immunobullous disorders. Clinicians should be aware of the occurrence of serum sickness symptoms during RTX administration, and prompt initiation of corticosteroid therapy is crucial in these patients. Additionally, RISS may occur with subsequent RTX doses and patients should be counseled accordingly.

View Article and Find Full Text PDF

Rituximab-induced gut microbiota changes in Chinese neuromyelitis optica spectrum disorders.

Mult Scler Relat Disord

June 2024

Department of Neurology, The First Affiliated Hospital Nanchang University, Nanchang, Jiangxi Province, 330006, China. Electronic address:

Background: Recent evidence shows that immunosuppressive agents can affect the gut microbiota in autoimmune diseases. However, the relationship between the gut microbiome and B-cell depletion immunotherapy in neuromyelitis optica spectrum disorder (NMOSD) remains poorly understood.

Objectives: To evaluate the distinct intestinal microbial patterns and serum cytokine levels after short-term rituximab treatment (three months) in patients with NMOSD.

View Article and Find Full Text PDF

[Two cases of rituximab induced serum sickness in children with nephrotic syndrome].

Zhonghua Er Ke Za Zhi

May 2024

Department of Pediatrics, the First Affiliated Hospital of Xiamen University, Pediatric Key Laboratory of Xiamen, Institute of Pediatrics, School of Medicine, Xiamen University, Xiamen 361003, China.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!